Skip to main content

Q3 GDP, core sector numbers, fiscal deficit data & more

To keep you updated, we send Daily Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here
The Economic Times

Daily Newsletter

Subscribe to ET Prime

Tue, Feb 28, 2023 | 05:48 PM IST
#NRI#EV Calculator#NewsLive!#WebStories
Top stories of the day
Q3 GDP growth moderates to 4.4% amid high inflation, weak demand Q3 GDP growth moderates to 4.4% amid high inflation, weak demand
"GDP at Constant (2011-12) Prices in Q3 2022-23 is estimated at ₹40.19 lakh crore, as against ₹38.51 lakh crore in Q3...
Core sector output increases by 7.8% in January
Apr-Jan fiscal deficit at 67.8% of revised FY23 aim
Airtel beats Jio in RMS share growth for 3Q
Oppo India appoints Alfa Wang as president
Airtel, Vi back pay-as-you-use tariff policy
Importers hedge less, assured by RBI's Re support
MV Ganga Vilas completes its 50-day river journey
These are income tax slabs to save tax for FY 2022-23
ET India Rising: Ashu Suyash maps playbook for achieving resilient, inclusive economic growth
NRI reckoner
Germany wants to make it easier for Indian IT workers to get work visa
Germany has been improving its legal framework to make itself more attractive for software developers and those with IT development skills, the Chancellor said. This has been a priority for his government this year, he added.

Top Gainers

NSE
6 companies (largecap) appreciated more than 5%
Adani Ent. 14.27%
Data Patterns (India) Ltd. 8.56%
More from Gainers

Top Losers

NSE
1 company (largecap) price decreased more than -5%
Vedanta -6.61%
More from Losers

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
More From our Partners
What makes the OnePlus 11 5G a stellar smartphone that will last long?
The OnePlus 11 5G will provide a premium smartphone experience with its features and usability that will improve the tech aspect of lives for the better.
Adani Group's over-leveraging shows bad business practice, not con: Aswath Damodaran Adani Group's over-leveraging shows bad business practice, not con: Aswath Damodaran
"The Adani Group collectively carries about three times as much debt as it should, confirming that the group is over-...
Singapore Airlines to get a quarter of Air India
Bond yield reaches 7.45%: Returns from debt products are looking attractive, how to gain more from it
India okays $3.9 bn hydropower project near China border
Rel Retail aims to be world's biggest garment seller in 2 years
Sanctions headache may dent India's Russian oil deals
Lenders to retain credit limits of Adani Enterprises
New platform for complaints against social media cos
Court orders jail for Maiden Pharma execs
China says its eco recovery is still not solid
India Inc in for pre-pandemic level hikes
Air India to refurbish fleet by next year
High airfares are here to stay: AirAsia
After Ethanol, policy support for Biogas
Sisodia's arrest: How Delhi liquor scam unfolded
IFCI & EY to help streamline FAME scheme
Corporate India skilling staff on war footing
Adani to repay $790 mn loans by March: Report
More From our Partners
ET India Rising: NITI Aayog CEO on India's sweet spot in the global economy and engineering the golden age or Amrit Kaal

What will it take to mint an economic elixir for India@100? What is the action agenda for steering PM Modi's goal of India becoming a developed nation by 2047? NITI Aayog CEO Parameswaran Iyer delves into the challenges and opportunities of the future, from riding on the power of green fuel to transitioning to green energy, boosting a She economy, rebuilding the logistics labyrinth, and reimagining the role of governance through Digital 2.0, which is already causing an explosion in financial inclusion.
icon
Top Slideshow
Actresses who have turned entrepreneurs
Actresses who have turned entrepreneurs
icon
Top Video
No relief for Sisodia from Supreme Court
No relief for Sisodia from Supreme Court
Follow Us on ET:
Facebook Twitter YouTube LinkedIn
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
© 2023 Times Internet Limited.
To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today.
If you are having trouble viewing this newsletter, please click here
To unsubscribe or edit your subscriptions please click here

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More